{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:57:46Z","timestamp":1793055466499,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103121"],"award-info":[{"award-number":["82103121"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20200878"],"award-info":[{"award-number":["BK20200878"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013280","name":"Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013280","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010023","name":"Natural Science Research of Jiangsu Higher Education Institutions of China","doi-asserted-by":"publisher","award":["20KJB310014"],"award-info":[{"award-number":["20KJB310014"]}],"id":[{"id":"10.13039\/501100010023","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007824","name":"Soochow University","doi-asserted-by":"publisher","award":["KY2024273B"],"award-info":[{"award-number":["KY2024273B"]}],"id":[{"id":"10.13039\/501100007824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.intimp.2025.116126","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:07:45Z","timestamp":1767175665000},"page":"116126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["CHK1 inhibition by prexasertib sensitizes cisplatin-resistant malignant tumor cells via checkpoint abrogation and STAT1-driven PD-L1 upregulation"],"prefix":"10.1016","volume":"171","author":[{"given":"Jinjin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsha","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2025.116126_bb0005","doi-asserted-by":"crossref","first-page":"6928","DOI":"10.7150\/thno.43811","article-title":"Aurora-a\/SOX8\/FOXK1 signaling axis promotes chemoresistance via suppression of cell senescence and induction of glucose metabolism in ovarian cancer organoids and cells","volume":"10","author":"Sun","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2025.116126_bb0010","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2025.116126_bb0015","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: a review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"key":"10.1016\/j.intimp.2025.116126_bb0020","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1158\/1535-7163.MCT-14-1037","article-title":"LY2606368 causes replication catastrophe and antitumor effects through CHK1-dependent mechanisms","volume":"14","author":"King","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2025.116126_bb0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ctrv.2017.08.013","article-title":"DNA damage response inhibitors: mechanisms and potential applications in cancer therapy","volume":"60","author":"Carrassa","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2025.116126_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113797","article-title":"Natural products targeting the ATR-CHK1 signaling pathway in cancer therapy","volume":"155","author":"Ahmed","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.intimp.2025.116126_bb0035","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","article-title":"Targeting replication stress in cancer therapy","volume":"22","author":"da Costa","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2025.116126_bb0040","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.intimp.2025.116126_bb0045","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1038\/s41467-024-47215-6","article-title":"The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial","volume":"15","author":"Giudice","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.116126_bb0050","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1158\/1535-7163.MCT-19-0946","article-title":"CHK1\/2 inhibitor prexasertib suppresses NOTCH Signaling and enhances cytotoxicity of cisplatin and radiation in head and neck squamous cell carcinoma","volume":"19","author":"Zeng","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.intimp.2025.116126_bb0055","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ygyno.2022.09.019","article-title":"A phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer","volume":"167","author":"Konstantinopoulos","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.intimp.2025.116126_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106162","article-title":"Cell cycle checkpoints and beyond: exploiting the ATR\/CHK1\/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer","volume":"178","author":"Gupta","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2025.116126_bb0065","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1007\/s00262-021-02910-x","article-title":"Immune modulating activity of the CHK1 inhibitor prexasertib and anti-PD-L1 antibody LY3300054 in patients with high-grade serous ovarian cancer and other solid tumors","volume":"70","author":"Do","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.intimp.2025.116126_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115605","article-title":"The low-dose CHK1 inhibitor prexasertib triggers VDAC1 dephosphorylation to activate mtDNA-STING signaling and synergize immunotherapy","volume":"44","author":"Fu","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2025.116126_bb0075","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.intimp.2025.116126_bb0080","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-017-01883-9","article-title":"DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells","volume":"8","author":"Sato","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.intimp.2025.116126_bb0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1146\/annurev-med-042320-025136","article-title":"A tale of two checkpoints: ATR inhibition and PD-(L)1 blockade","volume":"73","author":"Ngoi","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.intimp.2025.116126_bb0090","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1158\/1078-0432.CCR-21-1010","article-title":"ATR inhibition induces CDK1-SPOP Signaling and enhances anti-PD-L1 cytotoxicity in prostate Cancer","volume":"27","author":"Tang","year":"2021","journal-title":"Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.intimp.2025.116126_bb0095","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1158\/0008-5472.CAN-11-0320","article-title":"RECQL1 and WRN proteins are potential therapeutic targets in head and neck squamous cell carcinoma","volume":"71","author":"Arai","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.intimp.2025.116126_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.oraloncology.2020.104945","article-title":"The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer","volume":"111","author":"Chen","year":"2020","journal-title":"Oral Oncol."},{"key":"10.1016\/j.intimp.2025.116126_bb0105","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41698-025-01064-8","article-title":"Integrative bioinformatics analysis and experimental validation identify CHEK1 as an unfavorable prognostic biomarker related to immunosuppressive phenotypes in soft tissue sarcomas","volume":"9","author":"Rong","year":"2025","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.intimp.2025.116126_bb0110","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/ijc.28226","article-title":"Roles of Chk1 in cell biology and cancer therapy","volume":"134","author":"Zhang","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2025.116126_bb0115","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1124\/mol.110.067199","article-title":"Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in carcinoma cells","volume":"78","author":"Mitchell","year":"2010","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.intimp.2025.116126_bb0120","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-021-00431-4","article-title":"Programmed death ligand 1 signals in cancer cells","volume":"22","author":"Kornepati","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2025.116126_bb0125","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2025.116126_bb0130","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.intimp.2025.116126_bb0135","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12929-022-00803-4","article-title":"A chemical probe inhibitor targeting STAT1 restricts cancer stem cell traits and angiogenesis in colorectal cancer","volume":"29","author":"Chou","year":"2022","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.intimp.2025.116126_bb0140","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s41568-022-00537-3","article-title":"STAT proteins in cancer: orchestration of metabolism","volume":"23","author":"Li","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.intimp.2025.116126_bb0145","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s10565-021-09640-x","article-title":"Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells","volume":"39","author":"Ghelli Luserna Di Rora","year":"2023","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.intimp.2025.116126_bb0150","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1038\/onc.2011.135","article-title":"Chk1 is dispensable for G2 arrest in response to sustained DNA damage when the ATM\/p53\/p21 pathway is functional","volume":"30","author":"Lossaint","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.intimp.2025.116126_bb0155","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00280-014-2380-5","article-title":"Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors","volume":"73","author":"Sausville","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.intimp.2025.116126_bb0160","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1007\/s00204-023-03611-3","article-title":"SIRT3-dependent mitochondrial redox homeostasis mitigates CHK1 inhibition combined with gemcitabine treatment induced cardiotoxicity in hiPSC-CMs and mice","volume":"97","author":"Chen","year":"2023","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.intimp.2025.116126_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-016-0473-1","article-title":"Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine","volume":"36","author":"Isono","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.intimp.2025.116126_bb0170","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.intimp.2025.116126_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.114278","article-title":"Prexasertib exerts a synergistic effect on the antitumor activity of Lenvatinib through ALOX15-mediated ferroptosis in hepatocellular carcinoma","volume":"150","author":"Zhang","year":"2025","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.116126_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110709","article-title":"STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage","volume":"123","author":"Guo","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2025.116126_bb0185","article-title":"The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy","volume":"57","author":"Li","year":"2025","journal-title":"Ann. Med."},{"key":"10.1016\/j.intimp.2025.116126_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104702","article-title":"A comprehensive review on targeting diverse immune cells for anticancer therapy: beyond immune checkpoint inhibitors","volume":"210","author":"Liu","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925021150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925021150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:09:07Z","timestamp":1768979347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925021150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":38,"alternative-id":["S1567576925021150"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.116126","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CHK1 inhibition by prexasertib sensitizes cisplatin-resistant malignant tumor cells via checkpoint abrogation and STAT1-driven PD-L1 upregulation","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.116126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116126"}}